Evidence map›Paper›PMID 40786183›Full record

ArticleEJHaem2025

Machine Learning Algorithm to Explore Patients With Heterogeneous Treatment Effects of Clinically Significant CMV Infection and Non-Relapse Mortality After HSCT.

Takashi Toya, Yujiro Nakajima, Konan Hara, Satoshi Kaito, Tetsuya Nishida, Naoyuki Uchida, Naoki Shingai, Wataru Takeda, Yukiyasu Ozawa, Masatsugu Tanaka and 13 more

Abstract read
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Takashi ToyaHematology Division Tokyo Metropolitan Komagome Hospital Tokyo Japan.ORCID https://orcid.org/0000-0002-7436-972X
Yujiro NakajimaDepartment of Radiological Sciences Komazawa University Graduate School Setagaya Japan.
Konan HaraHematology Division Tokyo Metropolitan Komagome Hospital Tokyo Japan.
Satoshi KaitoHematology Division Tokyo Metropolitan Komagome Hospital Tokyo Japan.
Tetsuya NishidaDepartment of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Naoyuki UchidaDepartment of Hematology Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital Tokyo Japan.ORCID https://orcid.org/0000-0001-5952-5926
Naoki ShingaiHematology Division Tokyo Metropolitan Komagome Hospital Tokyo Japan.
Wataru TakedaDepartment of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan.
Yukiyasu OzawaDepartment of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Masatsugu TanakaDepartment of Hematology Kanagawa Cancer Center Yokohama Japan.
Satoshi YoshiharaDepartment of Respiratory Medicine and Hematology Hyogo Medical University Nishinomiya Japan.ORCID https://orcid.org/0000-0002-8537-2422
Yuta KatayamaDepartment of Hematology Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital Hiroshima Japan.
Tetsuya EtoDepartment of Hematology Hamanomachi Hospital Fukuoka Japan.
Masashi SawaDepartment of Hematology and Oncology Anjo Kosei Hospital Anjo Japan.
Shuichi OtaDepartment of Hematology Sapporo Hokuyu Hospital Sapporo Japan.
Hiroyuki OhigashiDepartment of Hematology Hokkaido University Hospital Sapporo Japan.
Satoru TakadaLeukemia Research Center Saiseikai Maebashi Hospital Maebashi Japan.
Keisuke KataokaDivision of Molecular Oncology National Cancer Center Research Institute Tokyo Japan.
Junya KandaDepartment of Hematology and Oncology Graduate School of Medicine Kyoto University Kyoto Japan.ORCID https://orcid.org/0000-0002-6704-3633
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan.
Masao OgataDepartment of Medical Oncology and Hematology Oita University Faculty of Medicine Oita Japan.
Ayumi TaguchiDepartment of Gynecology The University of Tokyo Bunkyo Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation Nagoya Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Clinically significant cytomegalovirus infection (csCMVi) and non-relapse mortality (NRM) remain serious concerns after allogeneic hematopoietic stem cell transplantation (HSCT), but subpopulations with heterogeneous treatment effects (HTEs) is unclear. Although machine learning (ML) algorithms have recently been applied to HSCT, the methodology has not been well elucidated. Methods: We developed a ML algorithm which combined weighting procedures and left-truncated and right-censored trees based on classification and regression tree algorithms to fit survival data with time-varying covariates and competing risks comprehensively. The Japanese large-scale registry data were applied to the algorithm to explore subpopulations with HTEs of csCMVi and NRM after HSCT. Its performance was evaluated by comparing their c-indices with those of the conventional Fine-Gray model. Results: A total of 10,480 patients were divided into training (75%) and test (25%) cohorts; the training cohort was used to develop the ML model. Using the model, patient CMV-seropositivity, patient age, and acute graft-versus-host disease were identified as important predictors of csCMVi. In addition, the patients were successfully classified by the estimated cumulative incidence of csCMVi, which varied from 22.7% at 0.5 year to 82.7%. This model also depicts interpretable survival trees in various settings. Similarly, the patients can be also classified based on the estimated 3-year NRM, which varied from 8.0% to 48.5%. C-indices of the ML and the Fine-Gray model using the test cohort showed comparable performance. Conclusion: A reliable, explainable, and interpretable ML model was developed to explore subpopulations with HTEs of csCMVi and NRM after HSCT.

Indexed as

cytomegalovirusrisk factorsstem cell transplantation

Identifiers

PMID40786183
PMCPMC12335206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.